Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
| ▸ | BUB1 | O43683 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.48 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269627 | 0.93 | MAPK14 (0.54) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL4884621 | 0.88 | MAPK14 (0.53) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL4887694 | 0.86 | MAPK14 (0.61) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL4887203 | 0.86 | MAPK14 (0.52) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL14269642 | 0.85 | MAPK14 (0.68) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL13715075 | 0.84 | MAPK14 (0.56) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL14269644 | 0.84 | MAPK14 (0.52) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL4877481 | 0.81 | MAPK14 (0.43) | MAPK14CYP2C9MAPK11HSPB1F7 | |
| SCHEMBL14269630 | 0.81 | ADORA2A (0.58) | MAPK14CYP2C9MAPK11HSPB1BUB1 | |
| SCHEMBL14269612 | 0.81 | MAPK14 (0.67) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051416-A1 | Novel Compounds | MAPK1, MAPKAPK2, MAPK6 | MAPK14 23/4885CYP2C9 2102/4885MAPK11 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.